Tumor Biology

, Volume 37, Issue 8, pp 10247–10256 | Cite as

Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway

  • Shihua Yao
  • Xiaowei Wang
  • Chunguang Li
  • Tiejun Zhao
  • Hai Jin
  • Wentao Fang
Original Article

Abstract

Antitumor activity of kaempferol has been studied in various tumor types, but its potency in esophagus squamous cell carcinoma is rarely known. Here, we reported the activity of kaempferol against esophagus squamous cell carcinoma as well as its antitumor mechanisms. Results of cell proliferation and colony formation assay showed that kaempferol substantially inhibited tumor cell proliferation and clone formation in vitro. Flow cytometric analysis demonstrated that tumor cells were induced G0/G1 phase arrest after kaempferol treatment, and the expression of protein involved in cell cycle regulation was dramatically changed. Except the potency on cell proliferation, we also discovered that kaempferol had a significant inhibitory effect against tumor glycolysis. With the downregulation of hexokinase-2, glucose uptake and lactate production in tumor cells were dramatically declined. Mechanism studies revealed kaempferol had a direct effect on epidermal growth factor receptor (EGFR) activity, and along with the inhibition of EGFR, its downstream signaling pathways were also markedly suppressed. Further investigations found that exogenous overexpression of EGFR in tumor cells substantially attenuated glycolysis suppression induced by kaempferol, which implied that EGFR also played an important role in kaempferol-mediated glycolysis inhibition. Finally, the antitumor activity of kaempferol was validated in xenograft model and kaempferol prominently restrained tumor growth in vivo. Meanwhile, dramatic decrease of EGFR activity and hexokinase-2 expression were observed in kaempferol-treated tumor tissue, which confirmed these findings in vitro. Briefly, these studies suggested that kaempferol, or its analogues, may serve as effective candidates for esophagus squamous cell carcinoma management.

Keywords

Kaempferol Esophagus squamous cell carcinoma EGFR Hexokinase-2 Glycolysis 

Notes

Acknowledgments

This work was funded by the National Natural Science Foundation of China (81301829) and the Key Project of Science and Technology Commission of Shanghai Municipality (15411951700).

Compliance with Ethical Standards

Conflicts of interest

None

References

  1. 1.
    Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: risk factors, screening and endoscopic treatment in western and eastern countries. World J Gastroenterol. 2015;21:7933–43.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Somerset SM, Johannot L. Dietary flavonoid sources in Australian adults. Nutr Cancer. 2008;60:442–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem. 2007;18:567–79.CrossRefPubMedGoogle Scholar
  5. 5.
    Azevedo C, Correia-Branco A, Araujo JR, Guimaraes JT, Keating E, Martel F. The chemopreventive effect of the dietary compound kaempferol on the mcf-7 human breast cancer cell line is dependent on inhibition of glucose cellular uptake. Nutr Cancer. 2015;67:504–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Diantini A, Subarnas A, Lestari K, Halimah E, Susilawati Y, Supriyatna, et al. Kaempferol-3-O-rhamnoside isolated from the leaves of Schima wallichii Korth. inhibits MCF-7 breast cancer cell proliferation through activation of the caspase cascade pathway. Oncol Lett. 2012;3:1069–72.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Huang WW, Tsai SC, Peng SF, Lin MW, Chiang JH, Chiu YJ, et al. Kaempferol induces autophagy through ampk and akt signaling molecules and causes g2/m arrest via downregulation of cdk1/cyclin b in sk-hep-1 human hepatic cancer cells. Int J Oncol. 2013;42:2069–77.PubMedGoogle Scholar
  8. 8.
    Mylonis I, Lakka A, Tsakalof A, Simos G. The dietary flavonoid kaempferol effectively inhibits hif-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem Biophys Res Commun. 2010;398:74–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Cho HJ, Park JH. Kaempferol induces cell cycle arrest in ht-29 human colon cancer cells. J Cancer Prev. 2013;18:257–63.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lee HS, Cho HJ, Yu R, Lee KW, Chun HS, Park JH. Mechanisms underlying apoptosis-inducing effects of kaempferol in ht-29 human colon cancer cells. Int J Mol Sci. 2014;15:2722–37.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH, Chen YC. Kaempferol inhibits angiogenesis and vegf expression through both hif dependent and independent pathways in human ovarian cancer cells. Nutr Cancer. 2009;61:554–63.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Luo H, Rankin GO, Li Z, Depriest L, Chen YC. Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chem. 2011;128:513–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Halimah E, Diantini A, Destiani DP, Pradipta IS, Sastramihardja HS, Lestari K, et al. Induction of caspase cascade pathway by kaempferol-3-rhamnoside in lncap prostate cancer cell lines. Biomed Rep. 2015;3:115–7.PubMedGoogle Scholar
  14. 14.
    Wu LY, Lu HF, Chou YC, Shih YL, Bau DT, Chen JC, et al. Kaempferol induces DNA damage and inhibits DNA repair associated protein expressions in human promyelocytic leukemia hl-60 cells. Am J Chin Med. 2015;43:365–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Song W, Dang Q, Xu D, Chen Y, Zhu G, Wu K, et al. Kaempferol induces cell cycle arrest and apoptosis in renal cell carcinoma through egfr/p38 signaling. Oncol Rep. 2014;31:1350–6.PubMedGoogle Scholar
  16. 16.
    Huang WW, Chiu YJ, Fan MJ, Lu HF, Yeh HF, Li KH, et al. Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma u-2 os cells. Mol Nutr Food Res. 2010;54:1585–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Filomeni G, Desideri E, Cardaci S, Graziani I, Piccirillo S, Rotilio G, et al. Carcinoma cells activate amp-activated protein kinase-dependent autophagy as survival response to kaempferol-mediated energetic impairment. Autophagy. 2010;6:202–16.CrossRefPubMedGoogle Scholar
  18. 18.
    Luo H, Rankin GO, Juliano N, Jiang BH, Chen YC. Kaempferol inhibits vegf expression and in vitro angiogenesis through a novel erk-nfkappab-cmyc-p21 pathway. Food Chem. 2012;130:321–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049–57.CrossRefPubMedGoogle Scholar
  21. 21.
    Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem. 1995;270:16918–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, et al. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2014;14:345–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Rho M, Kim J, Jee CD, Lee YM, Lee HE, Kim MA, et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res. 2007;27:251–8.PubMedGoogle Scholar
  24. 24.
    Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res: MCR. 2009;7:1438–45.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fonteyne P, Casneuf V, Pauwels P, Van Damme N, Peeters M, Dierckx R, et al. Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma. Histol Histopathol. 2009;24:971–7.PubMedGoogle Scholar
  26. 26.
    Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC. Aberrant expression of the glycolytic enzymes aldolase b and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep. 2008;19:1045–53.PubMedGoogle Scholar
  27. 27.
    Ogawa H, Nagano H, Konno M, Eguchi H, Koseki J, Kawamoto K, et al. The combination of the expression of hexokinase 2 and pyruvate kinase m2 is a prognostic marker in patients with pancreatic cancer. Mol Clin Oncol. 2015;3:563–71.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Hamabe A, Yamamoto H, Konno M, Uemura M, Nishimura J, Hata T, et al. Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-e1alpha in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci. 2014;105:1100–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wang J, Yu JM, Jing SW, Guo Y, Wu YJ, Li N, et al. Relationship between egfr over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus: a meta-analysis. Asian Pac J Cancer Prev: APJCP. 2014;15:5889–93.CrossRefPubMedGoogle Scholar
  30. 30.
    Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K, et al. Epidermal growth factor receptor (egfr) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget. 2014;5:6620–32.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer J Int Cancer. 2007;121:2225–32.CrossRefGoogle Scholar
  32. 32.
    Nothlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am J Epidemiol. 2007;166:924–31.CrossRefPubMedGoogle Scholar
  33. 33.
    Garcia-Closas R, Gonzalez CA, Agudo A, Riboli E. Intake of specific carotenoids and flavonoids and the risk of gastric cancer in Spain. Cancer Causes Control: CCC. 1999;10:71–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Bobe G, Sansbury LB, Albert PS, Cross AJ, Kahle L, Ashby J, et al. Dietary flavonoids and colorectal adenoma recurrence in the polyp prevention trial. Cancer Epidemiol, Biomarkers Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2008;17:1344–53.CrossRefGoogle Scholar
  35. 35.
    Zhang Q, Zhao XH, Wang ZJ. Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (kyse-510) by induction of g2/m arrest and apoptosis. Toxicol In Vitro: Int J Published Assoc BIBRA. 2009;23:797–807.CrossRefGoogle Scholar
  36. 36.
    Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277:7610–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, et al. Hexokinase-mitochondria interaction mediated by akt is required to inhibit apoptosis in the presence or absence of bax and bak. Mol Cell. 2004;16:819–30.CrossRefPubMedGoogle Scholar
  38. 38.
    Krasnov GS, Dmitriev AA, Lakunina VA, Kirpiy AA, Kudryavtseva AV. Targeting vdac-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets. 2013;17:1221–33.CrossRefPubMedGoogle Scholar
  39. 39.
    Xie F, Su M, Qiu W, Zhang M, Guo Z, Su B, et al. Kaempferol promotes apoptosis in human bladder cancer cells by inducing the tumor suppressor, pten. Int J Mol Sci. 2013;14:21215–26.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Law AA, Collie-Duguid ES, Smith TA. Influence of resistance to 5-fluorouracil and tomudex on [18f]fdg incorporation, glucose transport and hexokinase activity. Int J Oncol. 2012;41:378–82.PubMedGoogle Scholar
  41. 41.
    Jiang JX, Gao S, Pan YZ, Yu C, Sun CY. Overexpression of microrna-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol Med Rep. 2014;10:995–1002.PubMedGoogle Scholar
  42. 42.
    Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepato-Gastroenterology. 2009;56:355–60.PubMedGoogle Scholar
  43. 43.
    Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H, et al. Epidermal growth factor receptor (egfr) signaling regulates global metabolic pathways in egfr-mutated lung adenocarcinoma. J Biol Chem. 2014;289:20813–23.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, et al. Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of egfr signaling pathways in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21:5110–20.CrossRefGoogle Scholar
  45. 45.
    Chen GQ, Tang CF, Shi XK, Lin CY, Fatima S, Pan XH, et al. Halofuginone inhibits colorectal cancer growth through suppression of akt/mtorc1 signaling and glucose metabolism. Oncotarget. 2015;6:24148–62.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Zhuo B, Li Y, Li Z, Qin H, Sun Q, Zhang F, et al. Pi3k/akt signaling mediated hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. Biochem Biophys Res Commun. 2015;464:401–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shihua Yao
    • 1
    • 2
  • Xiaowei Wang
    • 2
  • Chunguang Li
    • 2
  • Tiejun Zhao
    • 2
  • Hai Jin
    • 2
  • Wentao Fang
    • 1
  1. 1.Department of Thoracic Surgery, Shanghai Chest HospitalShanghai Jiaotong UniversityShanghaiChina
  2. 2.Department of Thoracic Surgery, Changhai HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations